Open company graph database — free web & API
Login

InfroFront Inc.

株式会社インフロント株式会社インフロント(日本)Alias
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
6
§01

Basic information

BASIC
Head office
9F, A Building, 1-9-13 Nihonbashi Motomachi, Chuo-ku, Tokyo
Chief executive
Shin Kanaya
Capital
30,000,000
Employees (non-consolidated)
Employees (consolidated)
Start date
2001-04-01
End date
§02

Websites

1 DOMAINS
§03

Business

7
Medical Planning & Medical WritingConsultingBrandingInteractive CommunicationEvent & Global CommunicationMedia Planning, DTC, PREducation
§04

Related companies

6 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
アイジー・ホールディングス
Group
エムスリーグループ
Group
M3 Inc.
Alliance
IG-Holdings
IMPEC Co., Ltd.
Insight Eye Inc.
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

51 EVENTS

Established in Kanda Jimbōchō, Chiyoda-ku, Tokyo.Sources

Established in Kanda Jimbocho, Chiyoda-ku, Tokyo.Sources

Relocated to Naitō Kanda, Chiyoda-ku, Tokyo.Sources

Moved to Kanda in Chiyoda-ku, Tokyo.Sources

Commenced support for editing and production of guidelines in the ophthalmology field.Sources

Started supporting the editing and production of guidelines in the ophthalmology field.Sources

Supported "Viral Conjunctivitis Guidelines (2003)"Sources

Started supporting the editing and production of guidelines in the ophthalmology field. Supported 'Viral Conjunctivitis Guidelines (2003)', 'Contact Lens Practice Guidelines (2005)', 'Allergic Conjunctivitis Guidelines (2006)', and 'Infectious Keratitis Practice Guidelines (2007)'.Sources

Started supporting the editing and production of guidelines in the ophthalmology field. Supported "Viral Conjunctivitis Guidelines (2003)", "Contact Lens Practice Guidelines (2005)", "Allergic Conjunctivitis Guidelines (2006)", and "Infectious Keratitis Practice Guidelines (2007)".Sources

Started supporting the editing and production of guidelines in the field of ophthalmology. We are involved in supporting the guidelines 'Guidelines for Viral Conjunctivitis (2003)', 'Contact Lens Clinical Guidelines (2005)', 'Allergic Conjunctival Disease Guidelines (2006)', and 'Infectious Keratitis Clinical Guidelines (2007)'.Sources

Received the Nikkei Medical Award at the 10th Nikkei BP Advertising Awards. The winning entry was Takeda Pharmaceutical Company's international strategic product 'Brolipress' (antihypertensive drug).Sources

Relocated to Nihonbashi Kabutocho, Chuo-ku, Tokyo.Sources

Received the "Nikkei Medical Award" at the 10th Nikkei BP Advertising Awards. The award-winning work was Takeda Pharmaceutical Company Limited's international strategic product "Blopress" (hypertension treatment drug)Sources

Moved to Nihonbashi Kabutocho, Chuo-ku, Tokyo.Sources

Received the 'Nikkei Medical Award' at the 10th Nikkei BP Advertising Awards. The award-winning work was Takeda Pharmaceutical Company Limited's international strategic product 'Blopress' (hypertension treatment drug).Sources

Supported "Contact Lens Practice Guidelines (2005)"Sources

Received the Nikkei Medical Award for the second consecutive year at the 11th Nikkei BP Advertising Awards. The winning entry was Takeda Pharmaceutical Company's international strategic product 'Brolipress' (antihypertensive drug).Sources

Received the "Nikkei Medical Award" for the second consecutive year at the 11th Nikkei BP Advertising Awards. The award-winning work was Takeda Pharmaceutical Company Limited's international strategic product "Blopress" (hypertension treatment drug)Sources

Received the 'Nikkei Medical Award' for the second consecutive year at the 11th Nikkei BP Advertising Awards. The award-winning work was Takeda Pharmaceutical Company Limited's international strategic product 'Blopress' (hypertension treatment drug).Sources

Selected as 'Rising Company 2006' by Teikoku Databank.Sources

Selected as "Rising Company 2006" * by Teikoku Databank.Sources

Selected as 'Rising Company 2006' * by Teikoku Databank. * Emerging growing company selected by Teikoku Databank from companies whose most recent annual sales have increased by 100 million yen or more and sales have increased by 10% or more for the second consecutive term within 10 years of establishment, and whose corporate income has been announced within the second term. This represents about 1% of the 170,000 target companies.Sources

Selected as "Rising Company 2006" by Teikoku Databank.Sources

Selected as a 'Rising Company 2006' by Imperial Data Bank. * Companies founded or established within 10 years, with a recent annual sales of over 100 million yen and a consecutive 10% or greater revenue increase for two periods, and whose corporate taxable income was disclosed within two periods, were selected by Imperial Data Bank as emerging growth companies. About 1% of the approximately 170,000 target companies.Sources

Supported "Allergic Conjunctivitis Guidelines (2006)"Sources

Our website 'HeartFailure.com' was featured in the Nihon Keizai Shimbun 'Yū & eye' and NIKKEI NET 'Ikiki Health'.Sources

Our website "Heart Failure.com" was introduced in the Nihon Keizai Shimbun "Yu & eye" and NIKKEI NET "Ikiiki Kenko".Sources

Our website 'Heart Failure.com' was introduced in the Nihon Keizai Shimbun 'Yu & eye' and NIKKEI NET 'Ikiiki Kenko'.Sources

Received the Best Advertising Award at the 13th Nikkei BP Advertising Awards. The winning entry was Takeda Pharmaceutical Company's international strategic product 'Brolipress' (antihypertensive drug).Sources

Received "Nikkei BP Award Best Advertising Award" at the 13th Nikkei BP Advertising Awards. The award-winning work was Takeda Pharmaceutical Company Limited's international strategic product "Blopress" (hypertension treatment drug)Sources

Received 'Nikkei BP Award Best Advertising Award' at the 13th Nikkei BP Advertising Awards. The award-winning work was Takeda Pharmaceutical Company Limited's international strategic product 'Blopress' (hypertension treatment drug).Sources

Supported "Infectious Keratitis Practice Guidelines (2007)"Sources

Established a business partnership with overseas marketing company Jam Japan Marketing.Sources

Business tie-up with overseas marketing company "Jam Japan Marketing"Sources

Business tie-up with overseas marketing company 'Jam Japan Marketing'.Sources

Hosted a seminar titled 'Marketing Strategies and Success Stories of Pharmaceutical Companies in the United States, and the Latest Marketing Trends'.Sources

Held our seminar "Marketing Strategies and Success Stories of Pharmaceutical Companies in the United States and Latest Marketing Trends".Sources

Held our seminar 'Marketing Strategies and Success Stories of Pharmaceutical Companies in the United States and Latest Marketing Trends'.Sources

Our President, Kondo Katsumi, delivered a lecture at the 5th PBA Pharmaceutical Marketing Academy. The theme was 'Path to Innovative Pharmaceutical Promotion'.Sources

Katsumi Kondo, our President and CEO, gave a lecture at the 5th PBA Pharmaceutical Marketing Academy. The theme was "The Road to Innovative Drug Promotion".Sources

Our representative director and president, Kondo Katsumi, gave a lecture at the 5th PBA Pharmaceutical Marketing Academy. The theme was "The Path to Innovative Pharmaceutical Promotion".Sources

Katsumi Kondo, our President and CEO, gave a lecture at the 5th PBA Pharmaceutical Marketing Academy. The theme was 'The Road to Innovative Drug Promotion'.Sources

Commenced operation of the Secretariat of the Japanese Ophthalmology Allergy Research Association.Sources

Started operating as Secretariat of the Japan Ophthalmology Allergy Study GroupSources

Moved to Yaesu, Chuo-ku, Tokyo.Sources

Moved to Yaesu, Chuo-ku, TokyoSources

Joined the M3 Group.Sources

Moved to Nihonbashi-Honcho, Chuo-ku, Tokyo.Sources

Joined the M3 GroupSources

Moved to Nihonbashihoncho, Chuo-ku, TokyoSources

Susumu Kanaya was appointed Representative Director and President, and Katsumi Kondo was appointed Chairman.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information9010001073069
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社インフロント
Trade name (kana)
インフロント
Name in English
Corporation type
301
Address
〒103-0023 東京都中央区日本橋本町1丁目9番13号
Postal code
1030023
Prefecture code
13
City code
102
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-07-24
Change date
2017-01-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
1
Trade name image ID
Address image ID
Sequence number
2463542
METI gBizINFO9010001073069
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
9010001073069
Trade name
株式会社インフロント
Trade name (kana)
インフロント
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都中央区日本橋本町1丁目9番13号
Postal code
1030023
Prefecture
東京都
Prefecture code
13
City or district
中央区
City code
102
Street address
日本橋本町1丁目9番13号
Organisation type
301
Processing type
12
Correction type
1
Status
Representative
代表取締役 金谷 進
Capital
Employees
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
2001-03-07
Unified government qualification - grade
||C|
Unified government qualification - business items
301|306
Update date
2018-07-24
Key information
9010001073069
§09

Sources & updates

SOURCES
↑